Koole SN, van Lieshout C, van Driel WJ, et al. - Given that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) led to an improvement in recurrence-free and overall survival in patients with stage III ovarian cancer in the randomized open-label phase 3 OVHIPEC trial, researchers sought to examine if the addition of HIPEC to interval CRS in patients with ovarian cancer is cost-efficacious. A Markov health-state transition model was built to estimate costs and clinical outcomes. Based on the trial data, they determined incremental cost-effectiveness ratio (ICER), expressed as euros per quality-adjusted life-year (QALY), from a Dutch societal perspective, with a time horizon of 10 years. Outcomes revealed a substantial gain in QALYs on receiving treatment with interval CRS and HIPEC in patients with stage III ovarian cancer. In the Netherlands, the ICER is identified to be lesser than the willingness-to-pay threshold which suggests interval CRS and HIPEC as cost-effective for this patient population. Results thereby provide further support for reimbursing the costs of managing these patients with interval CRS and HIPEC in countries with similar health care systems.